Charlotte Admyre

Suggest Changes
Learn More
BACKGROUND Patients with chronic active ulcerative colitis (UC) are regarded as treatment failures and represent an area of high unmet medical need, as normally the only remaining option is(More)
BACKGROUND The Toll-like-receptor 9 (TLR-9) agonist cobitolimod (DIMS0150, Kappaproct®) is a promising therapeutic option for ulcerative colitis (UC) patients. AIMS The objectives of this post-hoc(More)